Home / Explainers / Peptide stacks, and the Wolverine stack
Practice · 7 min read
Peptide stacks, and the Wolverine stack
A stack is two or more compounds taken together. The word came out of bodybuilding, where it described combining steroids, and it moved across to peptides intact. Most named stacks are marketing rather than medicine, and the reasoning behind them is worth taking apart, because the flaw is the same every time.
01The named ones you will come across
These names travel through forums, podcasts and vendor sites. None is a recognised clinical protocol. Nobody has run a trial on any of them.
| Name | What is in it | Sold for |
|---|---|---|
| Wolverine stack | BPC-157 and TB-500 | Injury healing, recovery |
| The GH stack | CJC-1295 and Ipamorelin | Muscle, fat loss, sleep |
| Longevity stack | Epitalon, sometimes with thymosin peptides or NAD precursors | Anti-ageing |
| Nootropic stack | Semax with Selank | Focus, mood, cognition |
| Metabolic stack | MOTS-c with AOD-9604 or similar | Fat loss, insulin sensitivity |
The Wolverine name is a reference to the comic character who heals from anything. That is the level of scientific rigour in the naming, and it is a reasonable guide to the rigour elsewhere.
02Where the reasoning goes wrong
The argument for a stack is usually that the two compounds work through different mechanisms, so combining them should produce more than either alone. Applied to the Wolverine stack: BPC-157 is said to promote new blood vessel growth into damaged tissue, TB-500 is said to help cells migrate into it, so together they should cover more of the repair process.
That is a perfectly reasonable hypothesis. It is also just a hypothesis, and it contains a hidden step.
The argument assumes each compound works on its own in humans. Neither has been shown to. For BPC-157, a 2025 systematic review screened 544 articles and found one clinical study. For TB-500 as sold, there is no human trial evidence at all.
Zero plus zero is zero. Combining two compounds that have not been shown to work does not produce something that has been shown to work. It produces a combination that has also not been shown to work, and about which even less is known.
03What stacking actually multiplies
Every problem with buying one unlicensed compound applies twice, and some get worse than double.
- Identity and purity. Two vials, two sets of unverifiable contents. Blends sold premixed are worse again, because you cannot tell what ratio you have, or whether both compounds are present at all.
- Sterility. Two products, two chances of contamination, and often more injections.
- Attribution. If something good happens you cannot tell which compound did it. If something bad happens you cannot tell either, and neither can a doctor trying to help you.
- Interactions. There is no interaction data for a single unlicensed peptide. For a combination there is not even a theoretical framework. Nobody has looked.
- Cost. Worth saying plainly. Stacks are the mechanism by which one purchase becomes several, indefinitely.
04Why the names exist
A named stack does commercial work that a single compound cannot.
It raises the order value, obviously. It also makes a purchase feel like joining something rather than buying a chemical: a protocol with a name sounds established, and it transfers credibility that nothing has earned. And it makes the claims harder to check, because there is no single compound to search for and no trial to look up. Try searching for evidence on the Wolverine stack and you will find vendor pages and forum posts, because that is all there is.
Ask what the stack is called in the medical literature. Real combination therapies have unglamorous names, get trialled as combinations, and appear in guidelines. If a combination only has a nickname, that nickname is the product.
05Where combinations are genuinely used
None of this means combining drugs is inherently unsound. It is standard practice across medicine, and there are licensed combinations in this very field.
CagriSema is semaglutide and cagrilintide together, acting on two different appetite systems. That is the same argument the stack sellers make. The difference is what happened next: it went into the REDEFINE phase 3 programme, and REDEFINE 4 compared it head to head against tirzepatide. Tirzepatide won, and CagriSema missed its non-inferiority threshold.
That is what testing a combination looks like, and note the outcome. A plausible two-mechanism argument, developed by a major manufacturer with real resources, and the trial did not support it. The reasoning behind stacks is not stupid. It is just untested, and when this kind of reasoning does get tested it is often wrong.
06If you are going to do it anyway
This site does not publish doses, protocols or sourcing, and that is not going to change. But there are things worth knowing that are not any of those.
- Tell a doctor. Not for permission. So that if something goes wrong, the person treating you knows what is in you. This matters far more with two compounds than one.
- One thing at a time is more informative. Starting two compounds together guarantees you learn nothing about either.
- If you compete in a tested sport, stop reading and check. BPC-157, TB-500, CJC-1295 and ipamorelin are all prohibited by WADA at all times, and strict liability means intent is irrelevant.
- Report harm. The Yellow Card scheme covers licensed medicines, but the MHRA does act on intelligence about unlicensed products. If something happens, saying so may protect someone else.
If you want the evidence position on any individual compound in these stacks, each has a full record.